Literature DB >> 17920367

A meta-analysis of 94,492 patients with hypertension treated with beta blockers to determine the risk of new-onset diabetes mellitus.

Sripal Bangalore1, Sanobar Parkar, Ehud Grossman, Franz H Messerli.   

Abstract

Beta blockers used for the treatment of hypertension may be associated with increased risk for new-onset diabetes mellitus (DM). A search of Medline, PubMed, and EMBASE was conducted for randomized controlled trials of patients taking beta blockers as first-line therapy for hypertension with data on new-onset DM and follow-up for > or =1 year. Twelve studies evaluating 94,492 patients fulfilled the inclusion criteria. Beta-blocker therapy resulted in a 22% increased risk for new-onset DM (relative risk 1.22, 95% confidence interval [CI] 1.12 to 1.33) compared with nondiuretic antihypertensive agents. A higher baseline fasting glucose level (odds ratio [OR] 1.01, 95% CI 1.00 to 1.02, p = 0.004) and greater systolic (OR 1.05, 95% CI 1.05 to 1.08, p = 0.001) and diastolic (OR 1.06, 95% CI 1.01 to 1.10, p = 0.011) blood pressure differences between the 2 treatment modalities were significant univariate predictors of new-onset DM. Multivariate meta-regression analysis showed that a higher baseline body mass index (OR 1.17, 95% CI 1.01 to 1.33, p = 0.034) was a significant predictor of new-onset DM. The risk for DM was greater with atenolol, in the elderly, and in studies in which beta blockers were less efficacious antihypertensive agents and increased exponentially with increased duration on beta blockers. For the secondary end points, beta blockers resulted in a 15% increased risk for stroke, with no benefit for the end point of death or myocardial infarction. In conclusion, beta blockers are associated with an increased risk for new-onset DM, with no benefit for the end point of death or myocardial infarction and with a 15% increased risk for stroke compared with other agents. This risk was greater in patients with higher baseline body mass indexes and higher baseline fasting glucose levels and in studies in which beta blockers were less efficacious antihypertensive agents compared with other treatments.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17920367     DOI: 10.1016/j.amjcard.2007.05.057

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  68 in total

Review 1.  Sympathetic nervous system in obesity-related hypertension: mechanisms and clinical implications.

Authors:  Graziela Z Kalil; William G Haynes
Journal:  Hypertens Res       Date:  2011-11-03       Impact factor: 3.872

Review 2.  Beta-blockers: no longer an option for uncomplicated hypertension.

Authors:  Sripal Bangalore; Gayathri Kamalakkannan; Franz H Messerli
Journal:  Curr Cardiol Rep       Date:  2007-11       Impact factor: 2.931

Review 3.  Pharmacologic considerations in the positioning of beta-blockers in antihypertensive therapy.

Authors:  Domenic A Sica; Henry R Black
Journal:  Curr Hypertens Rep       Date:  2008-08       Impact factor: 5.369

4.  A randomized controlled trial of the effects of aerobic dance training on blood lipids among individuals with hypertension on a thiazide.

Authors:  Fatai A Maruf; Aderonke O Akinpelu; Babatunde L Salako
Journal:  High Blood Press Cardiovasc Prev       Date:  2014-06-24

Review 5.  Antihypertensive drugs and glucose metabolism.

Authors:  Christos V Rizos; Moses S Elisaf
Journal:  World J Cardiol       Date:  2014-07-26

Review 6.  Cardiovascular therapies and associated glucose homeostasis: implications across the dysglycemia continuum.

Authors:  Rhonda M Cooper-DeHoff; Michael A Pacanowski; Carl J Pepine
Journal:  J Am Coll Cardiol       Date:  2009-02-03       Impact factor: 24.094

Review 7.  Antagonist molecules in the treatment of angina.

Authors:  Ashish K Gupta; David Winchester; Carl J Pepine
Journal:  Expert Opin Pharmacother       Date:  2013-09-18       Impact factor: 3.889

8.  Lack of interaction of beta-cell-function-associated variants with hypertension on change in fasting glucose and diabetes risk: the Framingham Offspring Study.

Authors:  Jose M de Miguel-Yanes; Bianca Porneala; Michael J Pencina; Caroline S Fox; Jose C Florez; David S Siscovick; Josée Dupuis; James B Meigs
Journal:  J Hypertens       Date:  2013-05       Impact factor: 4.844

Review 9.  Optimal use of beta-blockers in high-risk hypertension: a guide to dosing equivalence.

Authors:  Janet B McGill
Journal:  Vasc Health Risk Manag       Date:  2010-06-01

Review 10.  Heart rate control with adrenergic blockade: clinical outcomes in cardiovascular medicine.

Authors:  David Feldman; Terry S Elton; Doron M Menachemi; Randy K Wexler
Journal:  Vasc Health Risk Manag       Date:  2010-06-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.